Original research article| Volume 76, ISSUE 1, P45-48, July 2007

Download started.


Monthly injectable contraceptive use by adolescents in Brazil: evaluation of clinical aspects



      This prospective noncomparative observational study evaluated the clinical symptoms, body weight and blood pressure of 38 adolescents receiving a monthly injectable contraceptive containing estradiol valerate 5 mg and norethisterone 50 mg.


      The volunteers, aged 16���19 years, were examined monthly during 1 year and asked about the following symptoms at baseline: dysmenorrhea, headache, breast tenderness, leg pain and irritability.


      There was a constant and gradual decline in each of the above symptoms over time, and there was a statistically significant difference between symptoms reported at the first visit and subsequent appointments. Body weight and blood pressure did not change significantly during the 1-year period. No pregnancies were observed.


      These findings suggest that monthly injectable contraception with estradiol valerate 5 mg/norethisterone 50 mg represents a highly effective and well-tolerated contraceptive for teens.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zabin L.S.
        • Hardy J.B.
        • Street R.
        • King T.M.
        A school-hospital and university-based adolescent pregnancy prevention program.
        J Reprod Med. 1984; 29: 421-426
        • Tyrer L.B.
        Oral contraceptive for the adolescent.
        J Reprod Med. 1984; 29: 551-559
        • Jacobucci M.S.B.M.
        • Guazzelli C.A.F.
        • Barbieri M.
        • Ara��jo F.F.
        • Moron A.F.
        Bleeding patterns of adolescents using a combination contraceptive injection for 1 year.
        Contraception. 2006; 73: 594-597
        • World Health Organization (WHO)
        Medical eligibility criteria for contraceptive use. Reproductive health and research.
        3rd ed. WHO, Geneva2004
        • Mishra G.D.
        • Dobson A.J.
        • Schofield M.J.
        Cigarette smoking, menstrual symptoms and miscarriage among young women.
        Aust N Z J Public Health. 2000; 24: 413-420
        • Altman D.
        Practical statistics for medical research. Chapman & Hall, London (England)1991: 250
        • Bassol S.
        • Cravioto M.C.
        • Durand M.
        • et al.
        Mesigyna once-a-month combined injectable contraceptive: experience in Latin America.
        Contraception. 2000; 61: 309-316
        • Hassan E.O.
        • El-Nahal N.
        • El-Hussinie M.
        Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt. Efficacy, causes of discontinuation, and side effects.
        Contraception. 1999; 60: 87-92
        • Kesseru E.V.
        • Aydinlik S.
        • Etchepareborda J.J.
        Multicentred, Phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5mg as a monthly injectable contraceptive; final three-year report.
        Contraception. 1994; 50: 329-337
        • Haiba N.A.
        • El-Habshy M.A.
        • Said S.A.
        Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.
        Contraception. 1989; 39: 619-632